Home BioMarin's FDA Panel: Revisiting Biotech's Biggest Battle
 

Keywords :   


BioMarin's FDA Panel: Revisiting Biotech's Biggest Battle

2015-11-30 16:10:16| Biotech - Topix.net

BioMarin's exon-skipping drug, drisapersen, has occupied biotechnology investors' minds over the past week. is a debilitating muscular disease that affects boys less than 10 years of age and slowly causes progressive muscle wasting resulting in loss of walking ability, and respiratory and cardiac failure with 100% death rate within few years.

Tags: panel battle biggest fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.11
28.11MF MFsoftbord twintown
28.11T800
28.11162
28.112 117
28.112CD+DVD
28.114
28.11Nike Iowa 90s
More »